Bionano Genomics Reports Q3 2026 Revenue Growth Driven by Consumables and Instrument Sales
Bionano Genomics (BNGO) reported third-quarter 2026 revenue of $8.3 million, a 12% increase year-over-year. The growth was primarily fueled by a 24% rise in consumables revenue and record sales of 9,870 flow cell units. While software revenue saw a significant decline of 31%, the company successfully improved its adjusted gross margin to 48% through disciplined cost management, reducing operating expenses by 12% compared to the previous year. The company is executing a long-term strategic plan aimed at achieving adjusted EBITDA neutrality by the end of 2027. Management provided optimistic full-year 2026 revenue guidance of $31 million to $33 million and set an ambitious 2027 target of $50 million to $54 million. Despite strong demand, leadership noted that supply constraints regarding silicon wafers have resulted in back orders and long lead times.
Tickers: $SPCX
Topics: Consumables Revenue Financial Guidance Operating Expenses Revenue Growth